Immunology & Cancer Immunotherapy Program Themes and Highlights
Members of the Immunology and Cancer Immunotherapy Research Program are investigating the following areas:
- Immune regulation
- Alteration of the tumor microenvironment (TME) for therapeutic benefit
- Translational Immunotherapy
Immunology and Cancer Immunotherapy Program Entrepreneurship
The Immunology and Cancer Immunotherapy Program has a notable history of entrepreneurship, with current and former members (Drs. Michael Fanger and Paul Guyre) having founded Medarex, in 1987, and Genmab in 1999.
Medarex (purchased by Bristoll Meyers Squib in 2009) developed the first immune checkpoint inhibitor drugs (ipilimumab and nivolumab) for cancer patients.